XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value of Financial Instruments - Change In Fair Value, Contingent Liabilities (Details) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Contingent Consideration Receivable | Discontinued Operations, Disposed of by Sale | Elusys Therapeutics    
Change in fair value    
Fair Value, Net Derivative Asset (Liability), Balance at the beginning $ 268,000  
Issuance of convertible promissory note, related party (268,000)  
Consideration Earn-out Receivable | Discontinued Operations, Disposed of by Sale | Elusys Therapeutics    
Change in fair value    
Fair Value, Net Derivative Asset (Liability), Balance at the beginning 1,720,000  
Change in fair value 1,000,000  
Fair Value, Net Derivative Asset (Liability), Balance at the ending 2,720,000  
Contingent Consideration | Pelican Therapeutics, Inc.    
Change in fair value    
Balance at the beginning   $ 12,224,614
Change in fair value   (990,500)
Balance at the ending   $ 11,234,114
Convertible Promissory Notes, Related Party    
Change in fair value    
Issuance of convertible promissory note, related party 1,982,000  
Accrued Interest 3,750  
Change in fair value 96,000  
Fair Value, Net Derivative Asset (Liability), Balance at the ending $ 2,081,750